monoclonal antibody  (Bio X Cell)

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: PD-1 H regulates GAM polarization to promote glioma malignancy and suppress T-cell immunity. ( A ) Flow cytometric analysis of CD206 expression in BV2 cells, used as an in vitro model of GAMs, with PD-1 H knockout (PD-1 H-KO and PD-1 H-KO#1) or negative control (PD-1 H-NC) under basal conditions (blank) or following IL-4 stimulation (M2) for 48 h. ( B ) Flow cytometric analysis of CD86 expression in PD-1 H-deficient or control BV2 cells under basal conditions (blank) or after IFN-γ stimulation (M1) for 48 h. ( C ) Phagocytic activity of PD-1 H-deficient and control BV2 cells, assessed by uptake of fluorescent microspheres (FluoSpheres) after 4 h incubation. ( D ) Cell viability of GL261 glioma cells cultured with conditioned media derived from PD-1 H-NC, PD-1 H-KO, PD-1 H-KO#1, lenti-NC, or PD-1 H-overexpressing BV2 cells, measured by CCK-8 assay at 24, 48, and 72 h (*** p < 0.001, **** p < 0.0001). ( E, F ) Transwell invasion assays of GL261 cells co-cultured with BV2 cells expressing different levels of PD-1 H. Representative images ( E ) and quantification of invading cells per field ( F ) Are shown (* p < 0.05). ( G, H ) Colony formation assay of GL261 cells cultured with conditioned medium from BV2 cells as indicated. Representative images ( G ) and quantification of colony numbers ( H ) are shown (* p < 0.05, ** p < 0.01). ( I, J ) Wound-healing assays of GL261 cells at 0 h and 48 h after scratch following treatment with BV2 cell–derived conditioned media. Representative images ( I ) and quantification of wound closure ( J ) Are shown (* p < 0.05, ** p < 0.01). ( K ) Antigen-specific proliferation of OT-I CD8+ T cells in the priming stage. Total lymph node cells were stimulated with OVA257-268 peptide and co-cultured with BV2 cells for 48 h. Representative CFSE histograms are shown. ( L ) Proliferation analysis of CD8+ T cells in the differentiation stage. Pre-primed T cells were co-cultured with BV2 cells under IL-2 stimulation for another 48 h. Relative proliferative capacity was quantified via derivative analysis of normalized CFSE signals. Data are presented as mean ± SD (** p < 0.01)

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: Expressing, In Vitro, Knock-Out, Negative Control, Control, Activity Assay, Incubation, Cell Culture, Derivative Assay, CCK-8 Assay, Colony Assay

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: PD-1 H expression and distribution in glioma. ( A ) Representative IHC images of PD-1 H in human glioma vs. normal brain tissue (scale bars, 200 μm). ( B ) Quantification of IHC scores for PD-1 H in glioma ( n = 27) and normal brain ( n = 5) samples (** p < 0.01). ( C ) Violin plots showing expression distribution of PD-1 H and other immune checkpoint molecules (TIM-3, LAG-3, TIGIT, CTLA-4, PD-L1, and PD-1) in glioma samples from the TCGA dataset. ( D ) Bulk RNA-seq of PD-1 H expression levels in glioma ( n = 702) and normal brain ( n = 423) samples based on RNA-seq data from TCGA and GTEx datasets (**** p < 0.0001). ( E ) UMAP plot showing single-cell RNA-seq data of glioma, colored by cell type (5.27 × 10 5 cells from 85 glioma samples, single-cell portal, SCP2389). ( F ) UMAP plot with PD-1 H expression intensity (color scale). ( G ) Bar chart showing the expression of PD-1 H in different cell clusters

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: Expressing, RNA Sequencing, Single Cell

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: PD-1 H expression in GAMs is associated with immune cell composition and clinical outcome in glioma. ( A–E ) Representative IHC staining of PD-1 H, CD68, CD163, CD80, and CD8 in a glioma specimen with low PD-1 H expression (patient-1). ( F–J ) Corresponding IHC staining of PD-1 H, CD68, CD163, CD80, and CD8 in a glioma specimen with high PD-1 H expression (patient-2). Scale bars, 200 μm. ( K–N ) Correlation analyses between PD-1 H and immune cell markers, including CD68, CD163, CD80 and CD8 in glioma samples ( n = 27). ( O–R ) Correlation analyses of expression levels between PD-1 H and immune checkpoint molecules, including TIM-3, PD-L1, PD-1, and CTLA-4 in glioma samples from the TCGA dataset ( n = 702, Spearman correlation, p < 0.001). ( S, T ) Kaplan–Meier survival curves of glioma patients stratified by PD-1 H expression levels in GAMs, including progression-free survival (PFS, S) and overall survival (OS, T) (Log-rank test)

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: Expressing, Immunohistochemistry

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: PD-1 H expression in GAMs promotes glioma progression and impairs antitumor T-cell responses in vivo. ( A ) Schematic illustration of the in vivo experimental design. C57BL/6 mice were intracranially implanted with GL261-luc glioma cells together with GAMs expressing PD-1 H overexpression (PD-1 H-OE), negative control (PD-1 H-NC), or PD-1 H knockout (PD-1 H-KO). Tumor growth was monitored by bioluminescence imaging at the indicated time points. ( B ) Representative bioluminescence images of tumor-bearing mice from each group at days 7, 14, and 21 after implantation. ( C ) Quantification of tumor bioluminescence radiance over time in mice receiving PD-1 H-OE, PD-1 H-NC, or PD-1 H-KO GAMs (* p < 0.05, *** p < 0.001). ( D ) Kaplan–Meier survival analysis of glioma-bearing mice in the indicated groups. Statistical significance was determined by log-rank test ( p < 0.001). ( E ) Flow cytometric analysis of GAM phenotypes isolated from glioma tissues. Representative histograms show expression of CD206 and MHC-II on GAMs from PD-1 H-OE, PD-1 H-NC, and PD-1 H-KO groups. ( F, G ) Representative flow cytometry histograms showing expression of PD-1 and TIM-3 on tumor-infiltrating CD8 + T ( F ) and CD4 + T ( G ) cells from each group

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: Expressing, In Vivo, Over Expression, Negative Control, Knock-Out, Imaging, Isolation, Flow Cytometry

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: PD-1 H regulates transcriptional programs and signaling pathways in GAMs. ( A ) Principal component analysis (PCA) of transcriptomic profiles from BV2 cells with PD-1 H-KO (KO), PD-1 H-NC (NC), or PD-1 H-OE (OE), showing distinct clustering among groups. ( B, C ) Volcano plot ( B ) and heatmap ( C ) showing differentially expressed genes (DEGs) in PD-1 H-OE vs. PD-1 H-NC. Upregulated and downregulated genes are highlighted. ( D, E ) Volcano plot ( D ) and heatmap ( E ) displaying DEGs in PD-1 H-KO vs. PD-1 H-NC. ( F, G ) Gene ontology (GO) enrichment analysis of DEGs from PD-1 H-OE vs. PD-1 H-NC ( F ) and PD-1 H-KO vs. PD-1 H-NC ( G ), with dot size indicating gene count and color representing statistical significance. ( H ) Western blot analysis of NF-κB, phosphorylated AKT (p-AKT), total AKT, in BV2 cells with different expression levels of PD-1 H. The PD-1H-blocking antibody 13F3 was applied as indicated (−/+)

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: Protein-Protein interactions, Western Blot, Expressing, Blocking Assay

Journal: Journal of Translational Medicine

Article Title: PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression

doi: 10.1186/s12967-026-08497-0

Figure Lengend Snippet: Therapeutic blockade of PD-1 H suppresses glioma progression in PD-1 H-/- host mice. ( A ) Schematic illustration of the in vivo experimental design. C57BL/6PD-1 H-/- mice were intracranially implanted with GL261-luc glioma cells together with PD-1 H-NC GAMs. Mice were treated with PBS or anti-PD-1 H monoclonal antibody at the indicated time points, and tumor growth was monitored by serial bioluminescence imaging. ( B ) Representative bioluminescence images of mice treated with PBS or anti-PD-1 H antibody at days 7, 14, 21, and 28 after implantation. ( C ) Quantification of tumor bioluminescence radiance over time in PBS- and anti-PD-1 H-treated mice, * p < 0.05. ( D ) Kaplan–Meier survival curves of glioma-bearing mice receiving PBS or anti-PD-1 H treatment, log-rank test, * p < 0.05

Article Snippet: Mice were subsequently treated with PBS or anti-PD-1 H monoclonal antibody (13F3, 300 μg/mouse, HY-P990145, MCE) every two days, a dosing regimen based on previous studies [ , ].

Techniques: In Vivo, Imaging

Journal: bioRxiv

Article Title: Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma

doi: 10.64898/2026.03.17.712479

Figure Lengend Snippet: A , C57/BL6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1), expressing a shRNA targeting ASS1 or a shRNA control. When tumors reached a mean of 100mm3, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control. The data are presented as the mean ± SEM for each group (n=10 mice per group). p-values were calculated using two-way ANOVA. B , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in B. The data are presented as the mean ± SEM (YUMM1.1shCTL n=9 tumors ; YUMM1.1shASS1 n=10 tumors). C , Deconvolution performed using CIBERSORTx performed on tumors from the experiment presented in A. D , Ratio CD8+ cells to malignant cells (Mal.) from the panel C is presented in tumor from the experiment presented in the panel A. E , Representative immunostaining of CD8+ T lymphocytes (red, CD8a) and nuclei (blue, DAPI) on frozen tumor sections of mice from panel A. F, Representation of CD8+ cells shown in D, the data are presented as the mean ± SEM (n=9 tumors). G. Representative immunostaining of CD8+ T cells and granzyme B on frozen tumor sections of mice from panel A.

Article Snippet: Antibodies InVivo Mab anti-mouse PD-1 (CD279), clone 29F.1A12 or InVivo Mab rat IgG2a isotype control, clone 2A3 were purchased from BioXCell, diluted in PBS and injected intraperitoneally (100μg in 100μL of PBS; 4mg.kg -1 per mouse).

Techniques: Expressing, shRNA, Control, Flow Cytometry, Immunostaining

Journal: bioRxiv

Article Title: Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma

doi: 10.64898/2026.03.17.712479

Figure Lengend Snippet: A , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line after 3 days of treatment with MDLA. HSP90 serves as a loading control. B , ASS1 enzymatic activity was performed in ICI-resistant YUMM1.1 cell line after 3 days of treatment with (n=3; mean ± SEM). C , Intracellular concentration of arginine was measure in ICI-resistant YUMM1.1 cells after 3 days of treatment with MDLA. (n=3; mean ± SEM). D. Schematic representation of the impact of arginine on the control upstream of mTORC1. E. Immunoprecipaption was performed on WM9 cells transfected with HA-tagged CASTOR1 and cultured for 3 days in the presence of different concentration of arginine and MDLA. Immunoblot showing the expression levels of indicated protein. F , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line. β-actine was use as a loading control. G , Immunoblot showing the expression levels of indicated protein in WM9 melanoma cell line. H , Renilla over Firefly luminescent ratio quantification in ICI-resistant YUMM1.1 cell line. I , Renilla over Firefly luminescent ratio quantification in WM9 melanoma cell line. J , YUMM1.1 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). K , WM9 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). L , Immunoblot showing the expression levels of indicated protein in cells from tumors of patients with metastatic melanoma. HSP90 serves as a loading control. M , Renilla over Firefly luminescent ratio quantification in cells from tumors of patients with metastatic melanoma (n=3; mean ± SEM). N , Cells isolated from tumors of patients with metastatic melanoma were treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). O , C57BL/6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1). When tumors reached a mean of 100mm 3 , mice were treated with MDLA (700mg.kg-1) or PBS, twice a day. Two days after the beginning of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 times. Mice were treated with an additional dose of anti-PD-1 or isotype IgG control at day 24. Tumor growth was monitored for 27 days. The data representing the tumor growth are presented as the mean ± SEM for each group (n=10 mice per group). p -values were calculated using two-way ANOVA. P , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in P. The data are presented as a ratio of percentage between CD45-positive cells versus CD45-negative cells. (n=10 tumors per group, mean ± SEM). Q , Percentage of CD45 and CD8a-double positive cells in tumors, determined by flow cytometry in tumors presented in P. (n=10 tumors per group, mean ± SEM).

Article Snippet: Antibodies InVivo Mab anti-mouse PD-1 (CD279), clone 29F.1A12 or InVivo Mab rat IgG2a isotype control, clone 2A3 were purchased from BioXCell, diluted in PBS and injected intraperitoneally (100μg in 100μL of PBS; 4mg.kg -1 per mouse).

Techniques: Western Blot, Expressing, Control, Activity Assay, Concentration Assay, Transfection, Cell Culture, Positive Control, Isolation, Flow Cytometry